Broad-spectrum antibiotic focusing on evidence-based approaches to minimize resistance. In humans: In veterinary medicine, co-amoxiclav, (in small animals); penicillin & streptomycin and oxytetracycline (in farm animals); penicillin and potentiated sulfonamides (in horses). Broad-spectrum antibiotic The term broad-spectrum antibiotic can refer to an antibiotic that acts on the two major bacterial groups, gram-positive and gram-negative, or any antibiotic that acts against a wide range of disease-causing bacteria. These medications are used when a bacterial infection is suspected but the group of bacteria is unknown (also called empiric therapy) or when infection with multiple groups of bacteria is suspected. This is in contrast to
A22 (antibiotic) A22 binds directly to the actin homolog MreB in its nucleotide-binding pocket, blocking simultaneous ATP binding. As a consequence, A22 inhibits MreB polymerization and thus disrupts the cytoskeleton of bacteria, causing defects of morphology and chromosome segregation. A22 (antibiotic) A22, also known as "S"-(3,4-dichlorbenzyl)isothiourea, is a chemical compound with antibiotic activity. It is colorless, hygroscopic, and light-sensitive. A22 acts as a reversible inhibitor of the bacterial cell wall protein MreB, causing bacterial rod-shaped cells to form coccoid cells. The antibiotic activity of A22 has been studied primarily in "Pseudomonas aeruginosa." However, A22 does not seem to be useful as an